Www.osteoporosis.ca 2005 OSC Recommendations for Bone Mineral Density Reporting Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD,

Slides:



Advertisements
Similar presentations
Chapter 68 Chapter 68 Fracture Risk Assessment: The Development and Application of FRAX ® Copyright © 2013 Elsevier Inc. All rights reserved.
Advertisements

2010 Guidelines Papaioannou A, et al. CMAJ 2010 Oct 12. [Epub ahead of print] Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis.
ADVANCES IN DIAGNOSIS & TREATMENT OF OSTEOPOROSIS Jerry Tenenbaum MD FRCPC Professor of Medicine:University of Toronto Mount Sinai Hospital.
Canadian Multicentre Osteoporosis Study (CaMos). What is CaMos? 10 year prospective population based epidemiologic study Sample frame: 40% Canadian of.
The FRAX tool for Osteoporosis Should all GP’s be calculating the Frax score prior to treatment Dr Sanjeev Patel Consultant Physician & Senior Lecturer.
Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist.
Assoc. Prof. Chatlert Pongchaiyakul, MD. Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, KKU, THAILAND Role of ultrasound.
2010 Guidelines Case Study #2: Mrs. BR 2010 Guidelines.
Chapter 66 Chapter 66 Clinical Use of Bone Densitometry Copyright © 2013 Elsevier Inc. All rights reserved.
a powerful tool to reduce the risk of future osteoporotic fractures The recognition and reporting of vertebral fractures: B Lentle,
WHO Osteoporosis Definition (1996)
"Bone density analysis using dual energy x-ray (DXA) bone absorptiometry in clinical investigation CEPEM Centro de Estudos e Pesquisas da Mulher - Rio.
Osteoporosis UBC Internal Medicine Program Dr. Mark Fok Dr. Maria Ashley.
BONE DENSITOMETRY ( DEXA SCAN) Dr Malith Kumarasinghe MBBS (Colombo)
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Selecting Candidates for Fracture Prevention Based on Risk Prediction Lubna Pal, MBBS, MRCOG, MS Assistant Professor Department of Obstetrics, Gynecology.
Interpretation of Bone mineral density
Denosumab NICE technology appraisal guidance 204 October 2010.
May 28 – 30, 2015, Montréal, Québec AN UNDERAPPRECIATED CAUSE OF MORBIDITY Sian E. Iles MD Associate Professor Dalhousie University Halifax Nova Scotia.
Identification of individuals at high- risk of fracture Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
“Known knowns, known unknowns, unknown unknowns….. Ronald Dumsfeld Senior Lecturer in Metabolic Bone Diseases.
1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium... 1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium...
Glucocorticoid-Induced Osteoporosis (GIO) Nguyen Thy Khue, MD, PhD Department of Endocrinology, HoChiMinh City University of Medicine and Pharmacy.
OSTEOPOROSIS CHOICE Decision Aid
Characteristics of a Swedish Patient Registry and Its Application On Unmet Needs Analysis Dr. Dan Mellström 1, Arun Krishna 2, Zhyi Li 3, Chun-Po Steve.
Fracture risk assessment
Hippisley-Cox, J., Bayly, J., Potter, J., Fenty, J. & Parker, C. (2007) Evaluation of standards of care for osteoporosis and falls in primary.
A Look at Osteoporosis Screening Guidelines Cynthia Phelan PGY
Internal Medicine Weekly Conference 1392 Internal Medicine Weekly Conference 1392 Alimohammad Fatemi Assistant Professor of Rheumatology Alimohammad Fatemi.
2010 Guidelines 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada Papaioannou A, et al. CMAJ 2010 Oct 12. [Epub.
Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :
Chapter 54 Chapter 54 HIV and Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Assessment of clinical risk factors for osteoporosis in patients with consisted fracture Author: Roxana Costache, 5 th year student, General Medicine Coordinators:
11 Quick Facts about Osteoporosis in Long-Term Care Homes Prevalence in LTC Who is at risk in LTC? Leading cause of fractures Reason for admission to LTC.
Sang-Rim Kim, Kwang Woo Nam, Yong-Geun Park, Sung-Rak Lee*, In Im**, Yong-Chan Ha*** Department of Orthopaedic Surgery, College of Medicine, Jeju National.
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
Osteoporosis: Measuring the Problem
Osteoporosis Dr Ramin Rafiei Alzahra Hospital Rheumatology Department.
Review: Osteoporosis Dr Roland Halil, BSc(Hon), BScPharm, ACPR, PharmD
Alimohammad Fatemi Assistant Professor of Rheumatology 1.
Five-year incident fracture risk assessed by quantitative multisite ultrasound: the Canadian Multicentre Osteoporosis Study. W. P. Olszynski 1, J. P. Brown.
HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;
Prevention and Treatment of Osteoporosis
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Osteodensitometry, Bone Biomechanics and Fracture Risk João Costa, Rui Miranda, Rui Pinto “Normal” Bone Introduction The bone formation takes place in.
Chapter 47 Assessing Fracture Risk: Who Should Be Screened? © American Society for Bone and Mineral Research Contributed by John Schousboe, Brent Taylor,
Osteopenia and Osteoporosis Bradley K. Harrison, MD.
NICE, FRAX & NOGG VTS meeting Jonathan Day 7 th April 2010.
Osteoporosis Dr Janet Horner Leeds Teaching Hospitals NHS Trust.
Chapter 34: Biochemical Markers of Bone Turnover in Osteoporosis Pawel Szulc and Pierre D. Delmas.
OSTEOPOROSIS Dr Annie Cooper Consultant Rheumatologist Royal Hampshire County Hospital Winchester.
R1 김형오 / Prof. 김덕윤 1.  Osteoporosis  Asian region is considered to be on the verge of an emerging osteoporosis epidemic  50% of the world’s osteoporotic.
Hwa-Jin Lee Department of nuclear medicine, Pusan University Hospital Study on the Analysis of Comparison with GE prodigy and FRAX Tool in Absolute Fracture.
Chapter 29: DXA in Adults and Children Judith Adams and Nick Bishop.
Rational Use of DXA-BMD
OSTEOPOROSIS Florence TREMOLLIERES, MD, PhD
Appropriate Osteoporosis Treatment by Family Physicians in Response to FRAX vs CAROC Reporting: Results From a Randomized Controlled Trial  Karen A. Beattie,
Osteoporosis Diagnosis 9/21/2018 OSTEOPOROSIS.
Ronald D. Emkey, MD, Mark Ettinger, MD 
2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada Papaioannou A, et al. CMAJ 2010 Oct 12. [Epub ahead of print].
Deciding on Pharmacological Treatment Post Fracture
Deciding on Pharmacological Treatment Post Fracture
Brian Lentle, MD, Angela M. Cheung, MD, PhD, David A
Figure 1: Assessment of basal 10-year risk of fracture with the 2010 tool of the Canadian Association of Radiologists and Osteoporosis Canada. Figure 1:
Canadian Association of Radiologists Technical Standards for Bone Mineral Densitometry Reporting  Kerry Siminoski, MD, FRCPC, Margaret O'Keeffe, MD, FRCPC,
Kerry Siminoski, MD, FRCPC, Margaret O'Keeffe, MD, FRCPC, Jacques P
Reporting the Results of DXA Scan
Interpretation The World Health Organization (WHO) Osteoporosis Guidelines (T Score vs Z score) A Z-score less than –2 indicates the diagnosis is below.
Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.
Presentation transcript:

OSC Recommendations for Bone Mineral Density Reporting Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD, FRCPC 2005 OSC Recommendations for Bone Mineral Density Reporting Siminoski K, Leslie WD, Brown JP, Frame H, Hodsman A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G. Recommendations for Bone Mineral Density Reporting in Canada. Can Assoc Radiol J 2005; 56: Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD, FRCPC

Definitions: BMD Results 1. Kanis JA, et al. J Bone Miner Res 1994;9: WHO, Geneva Status 1, 2 T-score Normal+2.5 to −1.0, inclusive OsteopeniaBetween −1.0 and −2.5 Osteoporosis≤−2.5 Severe osteoporosis≤−2.5 + fragility fracture

Who Should Be Treated for Osteoporosis? Long-term glucocorticoid therapy Start bisphosphonate therapy Start bisphosphonate therapy Obtain DXA BMD for follow-up Personal history of fragility fracture after age 40 Low DXA BMD (T-score <−2.5) Clinical risk factors (1 major or 2 minor) Non-traumatic vertebral compression deformities AND Low DXA BMD (T-score <−1.5) AND Low DXA BMD (T-score <−1.5) Consider therapy Consider therapy Repeat DXA BMD after 1or 2 years 2002 OSC Guidelines

WHAT’S WRONG WITH T-SCORES? Advantages Unitless Basis for the majority of osteoporosis guidelines Simplicity Disadvantages Depends on site measured Depends on technology Depends on reference database—population mean and standard deviation Only includes BMD information and not additional risk factors Adapted from Faulkner K. Osteoporos Int 2005;16(4):

Fracture Risk vs. BMD At Different Ages Fracture Risk vs. BMD At Different Ages BMD PREDICTS FRACTURES Hui et al. J Clin Invest 1988; 81:1804-9

AGET-Score = -1.0 T-Score = % 11 % 60 8 %16 % 7012 %23 % % 26 % Risk of Fractures Over 10 Years in Women

Proposed Change Previous OSC guidelines advised intervention based on WHO category as a marker of relative fracture risk. Now propose that an individual’s 10-year absolute fracture risk, rather than BMD alone, be used for fracture risk categorization

Objective: To propose a set of recommendations for optimal bone mineral density (BMD) reporting in postmenopausal women and older men to provide clinicians with both a BMD diagnostic category and a useful tool to assess an individual’s risk of osteoporotic fracture

5-STEPS IN 5-STEPS IN TREATING OSTEOPOROSIS TREATING OSTEOPOROSIS STEPS 1 and 2 STEPS 1 and 2 Begin with the table appropriate for the patient’s sex Identify the row that is closest to the patient's age

USING LOWEST T-SCORE TO FIND 10-YEAR FRACTURE RISK * * L1-4 (minimum 2 valid vertebrae), total hip, trochanter and femoral neck

USING LOWEST T-SCORE TO FIND 10-YEAR FRACTURE RISK - WOMEN Low Risk Moderate Risk High Risk

USING LOWEST T-SCORE TO FIND 10-YEAR FRACTURE RISK

USING LOWEST T-SCORE TO FIND 10-YEAR FRACTURE RISK - MEN Low Risk High Risk Moderate Risk

CATEGORIZATION BASED ON 10-YEAR FRACTURE RISK Absolute fracture risk in 10 years: low: <10% moderate: 10-20% high: >20%

5-STEPS IN 5-STEPS IN TREATING OSTEOPOROSIS TREATING OSTEOPOROSIS STEP 3 STEP 3 Determine the preliminary fracture risk category by using the lowest T-score from the recommended skeletal sites

5-STEPS IN 5-STEPS IN TREATING OSTEOPOROSIS TREATING OSTEOPOROSIS STEP 4 STEP 4 Evaluate clinical factors that may move the patient into an even higher fracture risk category

Additional Clinical Factors Certain clinical factors increase fracture risk independent of BMD. The most important are: –Fragility fractures after age 40 (especially vertebral compression fractures) –Systemic glucocorticoid therapy >3 months duration.

Additional Risk Factors Each factor effectively increases risk categorization to the next level: –from low risk to moderate risk, or –from moderate risk to high risk When both factors are present the patient should be considered at high risk regardless of the BMD result.

5-STEPS IN 5-STEPS IN TREATING OSTEOPOROSIS TREATING OSTEOPOROSIS STEP 5 STEP 5 Determine the individual’s final absolute fracture risk category.

52 year-old woman CASE EXAMPLE Lowest T-score –2.7 in total hip BMD done because of menopause (age 49) and family history of osteoporosis

CASE EXAMPLE

High Risk Moderate Risk Low Risk CASE EXAMPLE Low Risk Moderate Risk High Risk

Fracture Risk Category Moderate Risk CASE EXAMPLE

Fracture Risk Category High Risk Moderate Risk If Fragility Fracture History CASE EXAMPLE

CASE EXAMPLE

In Summary The OSC Recommends: Individual’s 10-year absolute fracture risk, rather than BMD alone, be used for fracture risk categorization Identify patient’s age/sex from table Use lowest T-score to determine preliminary fracture risk Evaluate other clinical factors that may move patient to higher risk category Determine individual’s absolute fracture risk

Endorsements Canadian Association of Nuclear Medicine Canadian Association of Radiologists Canadian Rheumatology Association International Society of Clinical Densitometry Society of Obstetricians and Gynecologists of Canada Canadian Society of Endocrinology and Metabolism Canadian Orthopedic Association College of Family Physicians of Canada